GPCR

Structure Therapeutics Inc.

Price Chart

Latest Quote

$45.61

+0.10 (+0.22%)

Current Price

Previous Close	$45.51
Open	$44.93
Day High	$46.29
Day Low	$43.98
Volume	1,098,500

Fetched: 2026-06-24T09:00:52

Stock Information

Shares Outstanding	71.07M
Total Debt	$5.79M
Cash Equivalents	$1.46B
Net Income	$-170.34M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$3.24B
EPS (TTM)	$-2.64
Exchange	NGM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$1.79B
Income	$-170.34M
Book/sh	$20.36
Cash/sh	$20.52
Employees	233

Financial Ratios

Quick Ratio	25.59
Current Ratio	26.16
Debt/Eq	0.40

Returns & Margins

ROA	-11.57%
ROE	-15.00%

Ownership

Insider Ownership	2.66%
Institutional Ownership	96.01%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-23.97
P/B	2.24

Analyst Data

Recommendation	strong_buy
Target Price	$104.59

Technical Indicators

SMA20	$41.09
SMA50	$42.37
SMA200	$48.47
RSI	81.37
ATR	2.3768

Shares Float	54.91M
Short Float	10.75%
Short Ratio	7.27
Volatility	-1.42
Rel Volume	1.64

Performance History

Week	+5.90%
Month	+17.58%
Quarter	-7.03%
6 Months	-26.97%
YTD	-33.04%
Year	+109.89%
3 Years	+47.41%
10 Years	+75.42%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-23	$45.61	1,344,700
2026-06-22	$45.51	1,149,600
2026-06-18	$44.51	1,151,900
2026-06-17	$45.00	1,028,000
2026-06-16	$42.91	714,800
2026-06-15	$43.07	711,700
2026-06-12	$42.93	545,900
2026-06-11	$43.30	1,023,100
2026-06-10	$41.53	1,158,800
2026-06-09	$41.25	1,873,100
2026-06-08	$37.77	764,700
2026-06-05	$37.58	520,900
2026-06-04	$39.06	643,100
2026-06-03	$37.50	473,400
2026-06-02	$37.19	854,200
2026-06-01	$38.55	670,500
2026-05-29	$39.34	506,500
2026-05-28	$40.17	285,100
2026-05-27	$39.54	573,100
2026-05-26	$39.58	398,800

About Structure Therapeutics Inc.

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671 and ACCG-3535, an oral small molecule amylin receptor agonist that is in phase1 clinical trial for the treatment of obesity; ANPA-0073, an oral small molecule APJ receptor agonist; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis. In addition, it develops programs, including glucose-dependent insulinotropic polypeptide receptor (GIPR) program, which identified multiple GIPR agonist, dual GLP-1R/GIPR agonist, and GIPR antagonist hits for small molecule GIPR modulation that has the potential to provide a treatment in obesity; and GCG program, which identified multiple GCG receptor (GCGR) agonist and dual GLP-1R/GCGR agonist hits for small molecule GCGR modulation. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

📰 Latest News

H.C. Wainwright Reiterates Buy Rating for Structure Therapeutics (GPCR)

Insider Monkey • 2026-06-17T15:55:38Z

Structure Therapeutics (GPCR) Reports Positive Phase 2 Weight Loss Data for Aleniglipron

Insider Monkey • 2026-06-08T03:44:52Z

Does Phase 2b Oral GLP-1 Data on Aleniglipron Change The Bull Case For Structure Therapeutics (GPCR)?

Simply Wall St. • 2026-06-07T13:18:37Z

If Viking Therapeutics Is Acquired, Here’s Who Wins

24/7 Wall St. • 2026-05-26T12:50:16Z

This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million

Motley Fool • 2026-05-24T14:39:48Z

This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter

Motley Fool • 2026-05-24T14:33:59Z

Lilly’s triple-acting obesity drug hits goal in Phase 3 trial

BioPharma Dive • 2026-05-21T09:38:53Z

Monashee Scales Back Its Bet on Structure Therapeutics

Motley Fool • 2026-05-20T19:47:07Z

This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million

Motley Fool • 2026-05-17T18:42:28Z

Structure Therapeutics Stock Is Up 47%, but One Fund Just Fully Exited a $2.6 Million Position

Motley Fool • 2026-05-10T11:59:01Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Total Expenses	$186,809,000	$158,228,000	$102,775,000	$52,561,000
Other Income Expense	$10,249,000	-	-	-
Net Non Operating Interest Income Expense	$35,873,000	$36,012,000	$13,391,000	$1,257,000
Total Other Finance Cost	$-35,873,000	$-36,012,000	$-13,391,000	$-1,257,000
Operating Expense	$186,809,000	$158,228,000	$102,775,000	$52,561,000
Other Operating Expenses	$-100,000,000	-	-	-
General And Administrative Expense	$61,554,000	$49,414,000	$32,672,000	$16,368,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-141,202,000	$-122,526,000	$-89,620,000	$-51,321,000
Net Interest Income	$35,873,000	$36,012,000	$13,391,000	$1,257,000
Normalized Income	$-149,298,710	$-122,526,000	$-89,620,000	$-51,321,000
Net Income From Continuing And Discontinued Operation	$-141,202,000	$-122,526,000	$-89,620,000	$-51,321,000
Total Operating Income As Reported	$-176,560,000	$-158,228,000	$-102,775,000	$-52,561,000
Net Income Common Stockholders	$-141,202,000	$-122,526,000	$-89,620,000	$-52,836,000
Net Income	$-141,202,000	$-122,526,000	$-89,620,000	$-51,321,000
Net Income Including Noncontrolling Interests	$-141,202,000	$-122,526,000	$-89,620,000	$-51,321,000
Net Income Continuous Operations	$-141,202,000	$-122,526,000	$-89,620,000	$-51,321,000
Pretax Income	$-140,687,000	$-122,216,000	$-89,384,000	$-51,304,000
Special Income Charges	$10,249,000	$0	$0	-
Operating Income	$-186,809,000	$-158,228,000	$-102,775,000	$-52,561,000
Net Income From Tax Loss Carryforward	-	-	-	-
Per Share
Diluted EPS	$-1.99	$-2.14	$-2.43	$-1.38
Basic EPS	$-1.99	$-2.14	$-2.43	$-1.38
Other
Tax Effect Of Unusual Items	$2,152,290	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-195,725,000	$-157,236,000	$-102,480,000	$-52,284,000
Total Unusual Items	$10,249,000	$0	$0	-
Total Unusual Items Excluding Goodwill	$10,249,000	$0	$0	-
Reconciled Depreciation	$1,333,000	$992,000	$295,000	$277,000
EBITDA (Bullshit earnings)	$-185,476,000	$-157,236,000	$-102,480,000	$-52,284,000
EBIT	$-186,809,000	$-158,228,000	$-102,775,000	$-52,561,000
Diluted Average Shares	$70,837,667	$57,286,667	$36,732,667	$38,243,176
Basic Average Shares	$70,837,667	$57,286,667	$36,732,667	$38,243,176
Diluted NI Availto Com Stockholders	$-141,202,000	$-122,526,000	$-89,620,000	$-52,836,000
Tax Provision	$515,000	$310,000	$236,000	$17,000
Gain On Sale Of Ppe	$10,249,000	$0	$0	-
Research And Development	$225,255,000	$108,814,000	$70,103,000	$36,193,000
Selling General And Administration	$61,554,000	$49,414,000	$32,672,000	$16,368,000
Other Gand A	$61,554,000	$49,414,000	$32,672,000	$16,368,000
Otherunder Preferred Stock Dividend	-	-	$0	$1,515,000
Preferred Stock Dividends	-	-	-	$1,515,000
Minority Interests	-	-	-	$0

Fetched: 2026-06-19

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$1,516,377,000	$864,843,000	$452,966,000	$-115,140,000
Total Assets	$1,583,918,000	$903,330,000	$482,017,000	$97,845,000
Total Non Current Assets	$13,615,000	$12,119,000	$8,409,000	$4,756,000
Other Non Current Assets	$717,000	$5,106,000	$45,000	$3,463,000
Current Assets	$1,570,303,000	$891,211,000	$473,608,000	$93,089,000
Other Current Assets	$24,106,000	$7,693,000	$6,285,000	$2,248,000
Receivables	$100,000,000	$0	-	-
Other Receivables	$100,000,000	-	-	-
Cash Cash Equivalents And Short Term Investments	$1,446,197,000	$883,518,000	$467,323,000	$90,841,000
Cash And Cash Equivalents	$799,623,000	$169,510,000	$129,792,000	$26,091,000
Prepaid Assets	-	-	-	-
Debt
Total Debt	$6,487,000	$3,862,000	$5,453,000	$260,000
Long Term Debt And Capital Lease Obligation	$3,609,000	$2,164,000	$4,013,000	$0
Current Debt And Capital Lease Obligation	$2,878,000	$1,698,000	$1,440,000	$260,000
Liabilities
Total Liabilities Net Minority Interest	$67,541,000	$38,487,000	$29,051,000	$212,985,000
Total Non Current Liabilities Net Minority Interest	$4,256,000	$2,466,000	$4,311,000	$199,975,000
Other Non Current Liabilities	$647,000	$302,000	$298,000	-
Current Liabilities	$63,285,000	$36,021,000	$24,740,000	$13,010,000
Payables And Accrued Expenses	$47,973,000	$27,033,000	$18,975,000	$9,206,000
Payables	$13,864,000	$8,024,000	$4,742,000	$6,183,000
Accounts Payable	$13,864,000	$8,024,000	$4,742,000	$6,009,000
Total Tax Payable	-	-	$356,000	$174,000
Income Tax Payable	-	-	$356,000	$174,000
Other Payable	-	-	-	-
Equity
Common Stock Equity	$1,516,377,000	$864,843,000	$452,966,000	$-115,140,000
Total Equity Gross Minority Interest	$1,516,377,000	$864,843,000	$452,966,000	$-115,140,000
Stockholders Equity	$1,516,377,000	$864,843,000	$452,966,000	$-115,140,000
Gains Losses Not Affecting Retained Earnings	$1,054,000	$914,000	$521,000	$-110,000
Other Equity Adjustments	$1,054,000	$914,000	$521,000	$-110,000
Retained Earnings	$-470,300,000	$-329,098,000	$-206,572,000	$-116,952,000
Preferred Securities Outside Stock Equity	-	$0	$0	$199,975,000
Other
Ordinary Shares Number	$212,513,000	$171,860,000	$139,220,000	$114,729,529
Share Issued	$212,513,000	$171,860,000	$139,220,000	$114,729,529
Tangible Book Value	$1,516,377,000	$864,843,000	$452,966,000	$-115,140,000
Invested Capital	$1,516,377,000	$864,843,000	$452,966,000	$-115,140,000
Working Capital	$1,507,018,000	$855,190,000	$448,868,000	$80,079,000
Capital Lease Obligations	$6,487,000	$3,862,000	$5,453,000	$260,000
Total Capitalization	$1,516,377,000	$864,843,000	$452,966,000	$-115,140,000
Additional Paid In Capital	$1,985,602,000	$1,193,010,000	$659,003,000	$1,921,000
Capital Stock	$21,000	$17,000	$14,000	$1,000
Common Stock	$21,000	$17,000	$14,000	$1,000
Long Term Capital Lease Obligation	$3,609,000	$2,164,000	$4,013,000	$0
Current Capital Lease Obligation	$2,878,000	$1,698,000	$1,440,000	$260,000
Pensionand Other Post Retirement Benefit Plans Current	$12,434,000	$7,290,000	$4,325,000	$3,544,000
Current Accrued Expenses	$34,109,000	$19,009,000	$14,233,000	$3,023,000
Net PPE	$12,898,000	$7,013,000	$8,364,000	$1,293,000
Accumulated Depreciation	$-2,969,000	$-1,636,000	$-644,000	$-349,000
Gross PPE	$15,867,000	$8,649,000	$9,008,000	$1,642,000
Leases	$1,536,000	$1,360,000	$1,360,000	$109,000
Construction In Progress	$1,278,000	$0	-	-
Other Properties	$11,552,000	$6,543,000	$7,096,000	$1,360,000
Machinery Furniture Equipment	$1,501,000	$746,000	$552,000	$173,000
Properties	$0	$0	$0	$0
Other Short Term Investments	$646,574,000	$714,008,000	$337,531,000	$64,750,000
Preferred Stock	-	$0	$0	$0

Fetched: 2026-06-19

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-225,813,000	$-117,926,000	$-81,655,000	$-46,275,000
Operating Activities
Operating Cash Flow	$-222,199,000	$-116,636,000	$-79,488,000	$-46,120,000
Cash Flow From Continuing Operating Activities	$-222,199,000	$-116,636,000	$-79,488,000	$-46,120,000
Operating Gains Losses	$-10,249,000	-	-	-
Investing Activities
Capital Expenditure	$-3,614,000	$-1,290,000	$-2,167,000	$-155,000
Investing Cash Flow	$89,796,000	$-358,909,000	$-268,342,000	$-62,108,000
Cash Flow From Continuing Investing Activities	$89,796,000	$-358,909,000	$-268,342,000	$-62,108,000
Financing Activities
Issuance Of Capital Stock	$665,708,000	$514,573,000	$472,296,000	$31,500,000
Financing Cash Flow	$762,516,000	$515,263,000	$451,531,000	$29,014,000
Cash Flow From Continuing Financing Activities	$762,516,000	$515,263,000	$451,531,000	$29,014,000
Net Other Financing Charges	$-2,638,000	$-1,796,000	$-21,565,000	$-2,519,000
Net Common Stock Issuance	$665,708,000	$514,573,000	$472,296,000	$0
Common Stock Issuance	$665,708,000	$514,573,000	$472,296,000	$0
Net Preferred Stock Issuance	-	-	$0	$31,500,000
Preferred Stock Issuance	-	-	$0	$31,500,000
Other
End Cash Position	$799,623,000	$169,510,000	$129,792,000	$26,091,000
Beginning Cash Position	$169,510,000	$129,792,000	$26,091,000	$105,305,000
Changes In Cash	$630,113,000	$39,718,000	$103,701,000	$-79,214,000
Proceeds From Stock Option Exercised	$99,446,000	$2,486,000	$800,000	$33,000
Net Investment Purchase And Sale	$93,410,000	$-357,619,000	$-266,175,000	$-61,953,000
Sale Of Investment	$640,789,000	$344,900,000	$151,181,000	$61,500,000
Purchase Of Investment	$-547,379,000	$-702,519,000	$-417,356,000	$-123,453,000
Net PPE Purchase And Sale	$-3,614,000	$-1,290,000	$-2,167,000	$-155,000
Purchase Of PPE	$-3,614,000	$-1,290,000	$-2,167,000	$-155,000
Change In Working Capital	$-88,041,000	$2,964,000	$6,966,000	$2,968,000
Change In Other Current Liabilities	$-2,296,000	$-1,591,000	$-315,000	$-361,000
Change In Other Current Assets	$4,389,000	$-5,061,000	$15,000	$-60,000
Change In Payables And Accrued Expense	$26,279,000	$11,024,000	$11,303,000	$3,694,000
Change In Accrued Expense	$21,514,000	$7,717,000	$12,163,000	$1,541,000
Change In Payable	$4,765,000	$3,307,000	$-860,000	$2,153,000
Change In Account Payable	$4,765,000	$3,307,000	$-860,000	$2,153,000
Change In Prepaid Assets	$-16,413,000	$-1,408,000	$-4,037,000	$-305,000
Change In Receivables	$-100,000,000	$0	$0	-
Other Non Cash Items	$2,556,000	$1,605,000	$655,000	$347,000
Stock Based Compensation	$28,991,000	$18,794,000	$8,191,000	$2,514,000
Amortization Of Securities	$-15,587,000	$-18,465,000	$-5,975,000	$-905,000
Depreciation Amortization Depletion	$1,333,000	$992,000	$295,000	$277,000
Depreciation And Amortization	$1,333,000	$992,000	$295,000	$277,000
Depreciation	$1,333,000	$992,000	$295,000	$277,000
Gain Loss On Investment Securities	$-10,249,000	-	-	-
Net Income From Continuing Operations	$-141,202,000	$-122,526,000	$-89,620,000	$-51,321,000

Fetched: 2026-06-19